digital currency providers, Related searches

Huitai Medical: Using raised funds and self-owned funds to increase capital of 700 million yuan to wholly-owned subsidiaries. Huitai Medical announced that the company held the 20th meeting of the second board of directors and the 17th meeting of the second board of supervisors on December 12, 2024, and reviewed and approved the Proposal on Using raised funds and self-owned funds to increase capital to wholly-owned subsidiaries. The company agreed to increase its capital by 700 million yuan to Shanghai Hongtong Industrial Co., Ltd., a wholly-owned subsidiary, of which 438 million yuan of interest-bearing loans provided to Shanghai Hongtong with raised funds were converted into capital increase, and 262 million yuan was increased with its own funds. After the capital increase is completed, the registered capital of Shanghai Hongtong will increase from RMB 18,489,300 to RMB 26,548,200, and it will remain a wholly-owned subsidiary of the company.Huangshan Capsule: It is planned to distribute a cash dividend of 0.27 yuan for every 10 shares. Huangshan Capsule announced that the company held the board of directors and the board of supervisors on December 13, 2024, and reviewed and approved the profit distribution plan for the first three quarters of 2024. According to the plan, the company plans to distribute a cash dividend of RMB27 to all shareholders for every 10 shares based on the existing total share capital of 299 million shares, with a total cash dividend of RMB8,075,700. This profit distribution will not send bonus shares, and capital reserve will not be converted into share capital.Huitai Medical: Using raised funds and self-owned funds to increase capital of 700 million yuan to wholly-owned subsidiaries. Huitai Medical announced that the company held the 20th meeting of the second board of directors and the 17th meeting of the second board of supervisors on December 12, 2024, and reviewed and approved the Proposal on Using raised funds and self-owned funds to increase capital to wholly-owned subsidiaries. The company agreed to increase its capital by 700 million yuan to Shanghai Hongtong Industrial Co., Ltd., a wholly-owned subsidiary, of which 438 million yuan of interest-bearing loans provided to Shanghai Hongtong with raised funds were converted into capital increase, and 262 million yuan was increased with its own funds. After the capital increase is completed, the registered capital of Shanghai Hongtong will increase from RMB 18,489,300 to RMB 26,548,200, and it will remain a wholly-owned subsidiary of the company.

On December 13th, Jiangsu Securities Regulatory Bureau issued an announcement that Yan Zhen had privately accepted the entrustment of customers to buy and sell securities during his tenure in the securities business department of Xuzhou Jianguo West Road of CITIC Securities (formerly known as the securities business department of Xuzhou Jiefang South Road of CITIC Securities). In violation of regulations, she was supervised to issue a warning letter and recorded it in the integrity file of the securities and futures market.The balance of A-share financing reached a new high in nine years. Since the fourth quarter, the net purchase amount of financing in 12 industries has exceeded 10 billion yuan. As of December 12, the balance of A-share financing was 1,882.656 billion yuan, a new high since August 2015. Since the fourth quarter, the market financing balance has grown rapidly. The latest financing balance was 1,882.656 billion yuan, an increase of 452.006 billion yuan or 31.59% compared with the financing balance of 1,430.650 billion yuan on September 30. During the period, the net purchase amount of financing in 12 industries exceeded 10 billion yuan. Electronics, computers, non-bank finance and machinery and equipment ranked in the top four, with the amounts of 77.849 billion yuan, 50.709 billion yuan, 49.201 billion yuan and 31.068 billion yuan in turn. In proportion, the latest financing balance of electronics, mechanical equipment and computers increased by more than 50% compared with that before the fourth quarter; The growth rate of media, communications and automobiles is also higher than 40%. In terms of individual stocks, Oriental Fortune received the most financing customers, with a net purchase amount of 15.892 billion yuan; SMIC ranked second with a net purchase of 5.515 billion yuan; Jianghuai Automobile ranked third with a net purchase of 4.122 billion yuan. Among the TOP20 stocks, there are many non-bank financial, automobile, computer and semiconductor stocks, accounting for 50% of the total. (data treasure)Liu Jianchao met with Egyptian Foreign Minister Abdul Ati. On December 13th, Liu Jianchao, Minister of the International Liaison Department of the CPC Central Committee, met with Egyptian Foreign Minister Abdul Ati in Beijing. The two sides exchanged views on implementing the important consensus of the two heads of state, strengthening inter-party exchanges, strengthening political dialogue and humanities exchanges, and promoting the construction of a community of destiny between China and Egypt facing the new era. (Xinhua News Agency)

Huawang Technology: Zhang Yancheng, the director, plans to reduce the company's shares by no more than 0.3443%. Huawang Technology announced that Zhang Yancheng, the company's director and senior manager, plans to reduce the company's shares by no more than 1.6 million shares through centralized bidding on the Shanghai Stock Exchange within three months after the announcement date, accounting for 0.3443% of the company's total share capital. The reduction price will be determined according to the market price. Zhang Yancheng currently holds 6,671,700 shares of the company, accounting for 1.4357% of the company's total share capital.Kang Enbei: Amikacin Sulfate Injection is planned to win the bid for the tenth batch of national centralized drug purchase. On December 12th, Kang Enbei and its wholly-owned subsidiary Jinhua Kang Enbei participated in the bidding for the tenth batch of national centralized drug purchase organized by the National Joint Procurement Office for Centralized Drug Purchase and Use. After the bid opening and bid evaluation by the Joint Procurement Office, the company's product Amikacin Sulfate Injection plans to win the bid for this centralized procurement, and the supply provinces have been selected according to the market potential of each province. The successful results will be officially released after being publicized by the Joint Procurement Office. Amikacin sulfate injection is suitable for the treatment of serious infections caused by Pseudomonas aeruginosa, other Pseudomonas, Escherichia coli and other sensitive gram-negative bacilli and Staphylococcus (methicillin-sensitive strains). Compared with the original price, the price of the product to be selected this time has dropped to a certain extent.Analysis: the potential weakness of Canada's manufacturing industry still exists. Forexlive: Canada's manufacturing industry rebounded strongly, mainly driven by petroleum products and automobiles. However, the year-on-year data decline shows that some potential weakness still exists.